Andria L. Bennett
- Democratic
Primary
This Act would prohibit insurers and pharmacy benefit managers from engaging in the practice of "clawbacks". When the total cost of a prescription drug to an insurer or pharmacy benefits manager is less than a patient's co-pay, the insurer or pharmacy benefits manager keeps the difference in a practice known as a "clawback". According to a March 2018 report issued by the University of Southern California's Schaeffer Center for Health Policy & Economics based on the Center’s analysis of 2013 data from a large commercial insurer combined with data on national average drug reimbursements, almost 25% of filled pharmacy prescriptions involved a patient co-payment that exceeded the average reimbursement paid by the insurer by more than $2.00. The report further noted that overpayments were more likely to occur on claims for generic drugs than brand drugs and that the total overpayments in the Center’s sample amounted to $135 million.
Signed by Governor
Passed By Senate. Votes: 18 YES 3 ABSENT
Reported Out of Committee (Health & Social Services) in Senate with 5 On Its Merits
Assigned to Health & Social Services Committee in Senate
Passed By House. Votes: 38 YES 3 ABSENT
Amendment HA 1 to HB 24 - Passed In House by Voice Vote
Amendment HA 1 to HB 24 - Introduced and Placed With Bill
Reported Out of Committee (Economic Development/Banking/Insurance & Commerce) in House with 3 Favorable, 9 On Its Merits
Introduced and Assigned to Economic Development/Banking/Insurance/Commerce Committee in House
| Bill Text Versions | Format |
|---|---|
| HA 1 to HB 24 | PDF HTML |
| Bill Text | HTML PDF |
| Document | Format |
|---|---|
| No related documents. |
Data on Open States is updated periodically throughout the day from the official website of the Delaware General Assembly.
If you notice any inconsistencies with these official sources, feel free to file an issue.